Boston, Massachusetts 02215

  • Guided Navigation Bronchoscopy


The purpose of this study is to determine if the cone beam computed tomography (CBCT)-guided navigation bronchoscopy is better in diagnosing lung nodules compared to navigation bronchoscopy alone.

Study summary:

This clinical trial examines the effectiveness of a treatment comparing it to another known treatment. The U.S. Food and Drug Administration (FDA) has approved the navigation bronchoscopy as a treatment option for this disease. The U.S. Food and Drug Administration (FDA) has approved the Cone-Beam CT scan as a treatment option for this disease. This research study involves a screening period, a procedure and follow up visits. The names of the study interventions involved in this study are: - Computed tomography (CBCT)-guided navigation bronchoscopy (CBCT-guided NB) - Navigation bronchoscopy alone Participants will receive the study procedure and will be followed for up to 6 months. It is expected that about 136 people will take part in this research study.


Inclusion Criteria: - Participants ≥18 years old. - Participants with lesions having an intermediate pre-test probability of malignancy (pCA, 0.05 to 0.65) as determined by Swensen-Mayo nodule risk calculator and in whom bronchoscopic biopsy was determined to be the next best treatment step by the treating pulmonologist. - Participants with higher risk lesions (pCA > 0.65) in need of a diagnosis for nonsurgical treatment or prior to surgery. - Participants are willing and able to provide informed consent. Exclusion Criteria: - The participant is pregnant as confirmed by urine or serum pregnancy testing. - There is a predetermined plan to pursue stereotactic body radiation therapy (SBRT) in the event of a nondiagnostic study procedure in participant's with a nodule in the outer 1/3 lung zone (i.e. The participant would not go on for a CT guided TTNA). - Lacked fitness according to physician judgement to undergo bronchoscopy. - Contraindication for temporary interruption of the use of anticoagulant therapy. - Uncontrolled or irreversible coagulopathy. - Known allergy for lidocaine. - Uncontrolled pulmonary hypertension. - Recent (< 4 weeks) and/or uncontrolled cardiac disease. - Compromised upper airway (eg concomitant head and neck cancer or central airway stenosis such that endobronchial access is considered unsafe). - ASA classification ≥ 4. - COVID-19 positive participant at the time of procedure.



Primary Contact:

Principal Investigator
Fayez Kheir, MD
Beth Israel Deaconess Medical Center

Fayez Kheir, MD
Phone: (857) 207-4022

Backup Contact:


Location Contact:

Boston, Massachusetts 02215
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.